1. Home
  2. Faculty

Michael Tomasson, MD

Professor of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation

Current Positions

  • Professor of Internal Medicine-Hematology, Oncology, and Blood & Marrow Transplantation

Education

  • MD, Stanford University, Stanford, California, United States
  • Resident, Stanford University Hospitals, Stanford, California
  • Fellow, Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Research Fellow, Hematology and Oncology, Brigham and Women's Hospital, Boston, Massachusetts

Graduate Program Affiliations

Licenses & Certifications

  • Medical License, Iowa Board of Medicine

Selected Publications

  • Soodgupta, D., Pan, D., Cui, G., Senpan, A., Yang, X., Lu, L., Weilbaecher, K. N., Prochownik, E. V., Lanza, G. M. & Tomasson, M. H. (2015). Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma. Molecular cancer therapeutics 14 (6) 1286-94. DOI: 10.1158/1535-7163.MCT-14-0774-T. PMID: 25824336. PMCID: PMC4571491.
  • Amend, S. R., Wilson, W. C., Chu, L., Lu, L., Liu, P., Serie, D., Su, X., Xu, Y., Wang, D., Gramolini, A., Wen, X. Y., O'Neal, J., Hurchla, M., Vachon, C. M., Colditz, G., Vij, R., Weilbaecher, K. N. & Tomasson, M. H. (2015). Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types. PloS one 10 (5) e0127828. DOI: 10.1371/journal.pone.0127828. PMID: 26020268. PMCID: PMC4447437.
  • Pan, D., Kim, B., Hu, G., Gupta, D. S., Senpan, A., Yang, X., Schmieder, A., Swain, C., Wickline, S. A., Tomasson, M. H. & Lanza, G. M. (2015). A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy. Nanomedicine (London, England) 10 (2) 241-51. DOI: 10.2217/nnm.14.101. PMID: 25600969. PMCID: PMC4665613.
  • Fiala, M. A., Stockerl-Goldstein, K. E., Tomasson, M. H., Vij, R., Wildes, T. M., Finney, J. D. & Liu, J. (2015). Socioeconomic status is independently associated with overall survival in patients with multiple myeloma. Leukemia & lymphoma 56 (9) 2643-9. PMID: 25651424. DOI: 10.3109/10428194.2015.1011156.
  • Miller, C. A., White, B. S., Dees, N. D., Griffith, M., Welch, J. S., Griffith, O. L., Vij, R., Tomasson, M. H., Graubert, T. A., Walter, M. J., Ellis, M. J., Schierding, W., DiPersio, J. F., Ley, T. J., Mardis, E. R., Wilson, R. K. & Ding, L. (2014). SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS computational biology 10 (8) e1003665. DOI: 10.1371/journal.pcbi.1003665. PMID: 25102416. PMCID: PMC4125065.
  • Carson, K. R., Bates, M. L. & Tomasson, M. H. (2014). The skinny on obesity and plasma cell myeloma: a review of the literature. Bone Marrow Transplantation 49 (8) 1009–1015. DOI: 10.1038/bmt.2014.71.
  • Wang, T. F., Ahluwalia, R., Fiala, M. A., Trinkaus, K. M., Cox, D. P., Jaenicke, M., Moliske, C. C., Carson, K. R., Wildes, T. M., Tomasson, M. H., Stockerl-Goldstein, K. E. & Vij, R. (2014). The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. Leukemia & lymphoma 55 (2) 337-41. DOI: 10.3109/10428194.2013.803547. PMID: 23662990. PMCID: PMC3951876.
  • Tomasson, M. H. (2013). The Analog World : Michael Tomasson's bloggish thoughts. Michael Tomasson.
  • Mullins, C. D., Su, M. Y., Hucthagowder, V., Chu, L., Lu, L., Kulkarni, S., Novack, D., Vij, R. & Tomasson, M. H. (2013). Germinal center B-cells resist transformation by Kras independently of tumor suppressor Arf. PloS one 8 (6) e67941. DOI: 10.1371/journal.pone.0067941. PMID: 23825691. PMCID: PMC3692489.
  • Hurchla, M. A., Garcia-Gomez, A., Hornick, M. C., Ocio, E. M., Li, A., Blanco, J. F., Collins, L., Kirk, C. J., Piwnica-Worms, D., Vij, R., Tomasson, M. H., Pandiella, A., San Miguel, J. F., Garayoa, M. & Weilbaecher, K. N. (2013). The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 27 (2) 430-40. DOI: 10.1038/leu.2012.183. PMID: 22763387. PMCID: PMC3771507.